Abstract
IV. Conclusion 10 References 15 Table 1  21   Table 2  22   Table 3  24   Table 4 25 Table 5 26 Table 6 28 Table 3 . Timing Between Chemotherapy and Radiation Table 4 . Hematologic Toxicity Table 5 . Non-Hematologic Toxicities 
I. Introduction
Endometrial cancer is the most common gynecologic malignancy accounting for an estimated 42,160 new cases and 7,780 deaths in 2009 [1] .
Fortunately, most women present with early stage disease and can be cured with primary therapy, however women with metastatic or relapsed cancer have poor disease specific survival with current adjuvant therapy [2] [3] [4] [5] .
Patients identified with regional metastatic disease at the time of primary surgery have conventionally received tailored adjuvant radiotherapy. Adjuvant radiotherapy (pelvic or WART) in advanced stages has been shown to significantly reduce pelvic recurrence, however failures outside the radiation field have limited the effect on long term survival [3, 6, 7] . (Table 1) in an attempt to improve on the response rate, progression-free (PFS) and overall survival (OS) for women with advanced or recurrent endometrial cancer. These studies show that platinum-based combination therapy can improve response rates, [11] [12] [13] with the three drug regimen of paclitaxel, adriamycin, and cisplatin (TAP) being the most efficacious but also most toxic in phase III studies [11] . Phase II trials using the better tolerated combination of paclitaxel and carboplatin (TP) combinations have demonstrated response rates between 45-78% suggesting that the additional toxicity of adding adriamycin may not be merited prompting the Gynecologic Oncology Group to study these combinations head-to-head [14, 15] .
Given that radiation appears to provide excellent control of targeted tissues, but adds little systemic protection, some authors have suggested that combining chemotherapy and radiation therapy may be optimal in patients without overt disease in the upper abdomen. Homesley et al. reported the GOG experience with RT followed by chemotherapy observing reasonable efficacy despite that fact that 20% of patients were unable to complete all prescribed therapy, largely owing to hematologic toxicity possibly due to the marrowsuppressing effects of the radiation [16] .
The current protocol was undertaken in response to recent retrospective reports suggesting that protocols "sandwiching" radiation therapy between 2 shorter courses of platinum and taxane based chemotherapy may be less toxic with equal or superior efficacy. By delivering adjuvant therapy in a sequential 'sandwich' fashion, we believe response rates will be optimized while limiting toxicities. The primary aim of our study was to determine the efficacy of administering docetaxel and carboplatin with radiotherapy in a 'sandwich' fashion in the treatment of advanced stage or recurrent endometrial cancer. 
II. Materials and Methods

Patient Eligibility
Radiation Therapy
Radiotherapy was initiated within 4 weeks of the 3 rd cycle of chemotherapy following adequate hematologic recovery. Radiation was delivered using a 4 field technique to the pelvis using photon beams of 18 or 25 MV. Daily fraction size was 175 cGy per day for 5 days per week. The total dose to the pelvic isocenter was 4550 cGy and to the center of the paraaortic nodal tissue (if nodes were involved) between 4300 and 4500 cGy. The volume of irradiation was dependent on the extent of disease found at the time of hysterectomy or recurrence. All patients received pelvic irradiation. For patients with positive paraaortic nodes, the fields were expanded to encompass both the pelvic and paraaortic nodal chains. CT planning was used to design fields. Standard pelvic borders were applied with the superior border being the L5-S1 interspace and laterally fields were designed to encompass the vessels/nodes with a 1 cm margin. The superior border was extended to the T10-T11 interspace for paraaortic irradiation. High dose rate brachytherapy vaginal cuff boost was delivered for vaginal extensions, cervical involvement, lower uterine segment involvement, parametrial extensions or at the discretion of the treating radiation oncologist. The vaginal boost consisted of 1-3 HDR applications with the dose prescribed to the vaginal surface for a length of 4 cm. If more than a 2-week treatment interruption was required, patients were removed from protocol.
Toxicity was graded as per CTCAE version 3 as described above.
Patient Follow-Up
Patients were evaluated weekly during radiation therapy. Before every chemotherapy cycle patients had a physical examination, complete blood count and electrolytes were measured. All adverse effects were assessed and reported. Those thought to be related to protocol treatment were graded according to the CTCAE version 3. After completion of treatment, participants underwent disease assessment with imaging 4-6 weeks following their final chemotherapy. Patients were evaluated for disease progression and recurrence every 3 months for 2 years and then every 6 months annually.
Statistical Analysis
This study was designed as a two-stage trial with progression-free survival (PFS) of 9 months as the primary endpoint. The first stage involved enrolling 16 patients with termination if 8 or fewer had less than 9 month PFS. A total of 39 patients were needed in the second stage to evaluate the protocol and the treatment would have been rejected if 24 or fewer had less than 9 month PFS.
While patients with recurrent disease were eligible for the trial, they were not included in the analysis of PFS and patients were recruited until 39 patients with primary disease enrolled.
All patient baseline demographic and clinical characteristics were summarized using descriptive statistics. Overall survival (OS) was calculated from date of study enrollment to death or was censored at date of last contact for patients still alive. PFS was calculated from study enrollment date to the date of first known relapse or death or was censored at date of last contact for patients still alive and without tumor recurrence/progression; only patients with primary disease were included in this analysis. OS and PFS were censored at 3 years for all patients. Kaplan-Meier methods were used to estimate OS and PFS curves. Point estimates and 95% confidence intervals for OS and PFS are reported at 1, 2 and 3 years.
III. Results
Patient characteristics
Between Table 2 . Two patients were treated at the time of disease recurrence. Two participants were taken off protocol due to disease progression, 1 due to liver toxicity and 3 withdrew consent during treatment.
Chemotherapy
Thirty-five patients (85%) completed all six prescribed cycles of chemotherapy as per protocol. In the adjuvant setting, following a surgical staging procedure, there was a mean of 34 days (SD=12.1) until chemotherapy was started. Radiation therapy was started a mean of 31 days (SD=10.3)
following completion of the first three cycles of chemotherapy. There was a mean of 27 days (SD=8.4) from completion of radiotherapy until the fourth cycle of chemotherapy was started (Table 3) . One patient's pulmonary disease responded to chemotherapy so her physician elected to have her remain on chemotherapy instead of starting radiation and the patient was taken off trial.
Radiation
Two patients did not receive pelvic radiotherapy: 1 had persistent lung disease and therefore remained on chemotherapy and one declined treatment.
One patient received only 21Gy due to progression found in the lung during radiation. The median dose of external beam pelvic radiation was 45.5 Gy (range=21-60 Gy) and 15 patients received a median of 45.5 Gy to the paraaortic lymph nodes. Twenty five patients were administered brachytherapy at a dose of 700 cGy in a single fraction at 0.5 cm depth and four patients received 900 cGy in 3 fractions at 0.5 cm depth.
Toxicity
Hematologic toxicities are listed in Table 4 . Grade 3/4 neutropenia occurred in 17 patients, with one grade 3 and one grade 4 neutropenic fever observed prior to the addition of growth factor to the protocol. Grade 3/4 anemia occurred in 5 and 1 patients, respectively. There were 23 grade 3 and no grade 4 non-hematological toxicities. The greatest grade 3 non-hematological toxicities were anorexia (3 patients) and abdominal pain (3 patients). Neuropathy was mild with grade 1 neuropathy in seven patients and grade 2 in two patients (Table 5 ).
Response
Patients were followed for a median of After excluding the two patients enrolled at recurrence, 9 of the 39 patients have progressed or died within 3 years of study enrollment. The Kaplan-Meier estimate and 95% CI for PFS at 1 year is 85.7% (69.0-93.8), at 2 years is 75.6%
(56.8-87.1), and at 3 years is 68.0% (44.6-83.2 ( Figure 2 ). There are an insufficient number of progressions to estimate the median progression-free survival in this patient population. While five of the 39 patients had not been followed for at least 9 months post-treatment at the time of the trial's completion, 30 patients had already achieved greater than 9 months of PFS and therefore we consider the treatment successful based on the parameters established prior to enrollment. Patterns of initial relapse are shown in Table 6 . The majority of relapses were distant occurring primarily in the lung. Two patients had lung metastasis at the time of starting chemotherapy. One patient had disease progression in the lung during the interval radiation despite resolution of her pulmonary nodules following 3 cycles of chemotherapy. There were two local relapses (one was a local and distant failure) that occurred within the radiated field.
IV. Conclusion
In this trial we demonstrate that the "sandwich" therapy using docetaxel and carboplatin is efficacious and well tolerated. Of the prospective studies treating patients in the "sandwich" fashion, we report the highest 3-year PFS (68%) and OS (82%) using the combination of carboplatin and docetaxel interposed with involved field radiation for women with advanced stage endometrial cancer.
The rationale of multi-modality therapy is to reduce disease dissemination as well as local-regional pelvic and retroperitoneal recurrences. Recent chemotherapy, interval radiation and subsequent chemotherapy. They reported a superior 3-year OS (88%) and PFS (69%) compared to those receiving radiation followed by chemotherapy or chemotherapy followed by radiation. We reported the same 3-year OS and a higher PFS (80%) in our retrospective review of the "sandwich" method for high risk endometrial cancer [19] .
Two authors have prospectively evaluated the use of the "sandwich" neuropathy. In the study by Lupe and colleagues examining paclitaxel and carboplatin interposed by radiation they reported that 31% of their patients experienced grade 3 or 4 toxicity with peripheral neuropathy and neutropenia being the most commonly cited [21] .
The activity of docetaxel in endometrial cancer has been previously reported. Katsumata and colleagues used docetaxel at 70 mg/m 2 every 3 weeks in stage III, IV or recurrent endometrial cancer with an overall response rate of 31% [23] . Günthert reported a response rate of 21% in previously untreated recurrent or metastatic endometrial cancer [24] . More recently the GOG conducted a phase II study in previously treated recurrent endometrial cancer patients studying the effects of docetaxel 36mg/m 2 administered weekly every 28 days. They reported modest activity with two (7.7%) partial responses and eight (30.8%) with stable disease [25] .
The decision to use docetaxel as opposed to paclitaxel and carboplatin over cisplatin is largely due to the grade 3 and 4 neuropathy seen in approximately 40% of patients when the combination of cisplatin and paclitaxel are used. Endometrial cancer patients often are older and many have previously-diagnosed diabetes; because of these factors, neuropathy tends to be a significant issue in this patient population. We believe that administration of docetaxel instead of paclitaxel decreased neurotoxicity allowing for completion of the 6 total prescribed courses of chemotherapy in this trial.
With the significantly different toxicity profiles of docetaxel and paclitaxel, in particular the lower incidence of neurotoxicity seen in docetaxel as well as the shorter infusion time, it offers not only a side effect advantage but a substantial clinical benefit for patients. Additionally, we have shown that with this particular regimen, patients have minimal delay between treatment modalities with on average about a month time period between the third cycle of chemotherapy to the start of radiotherapy and with less than a month before the fourth cycle of chemotherapy is started following radiation completion.
The low rate of recurrence in the radiation field is notable in our study.
There was one patient who had disease persistence in field following therapy completion and one who recurred with carcinomatosis throughout the abdomen and pelvis. These findings are similar to that of Lupe et al. who reported only two pelvic recurrences and one patient with a local and distant failure in their stage III/IV endometrial cancer patients treated in the "sandwich" fashion [21] . In studies using chemotherapy alone in the treatment of advanced endometrial cancer, pelvic recurrences have been reported to be as high as 46% [26] . Our findings with that of others suggest there may be improved pelvic control with the use of multimodality therapy as opposed to chemotherapy alone.
In our phase II study, we found the 'sandwich' protocol both feasible and well tolerated. Neutropenia was the most frequent toxicity. Furthermore, we found our 3-year PFS of 68% and OS of 82% to be higher than what has been previously reported in prospective studies indicating that this is an active and promising regimen for the treatment of patients with advanced stage endometrial cancer. Future randomized trials are necessary to compare chemotherapy and radiation given in the "sandwich" fashion to other means of sequencing these treatment modalities. 
